AveroBio's vision is to bring personalized gene therapy to the world. AveroBio target the root cause of genetic disease by introducing a functional copy of the affected gene into patients’ own hematopoietic stem cells (HSCs), with the goal of durably expressing the therapeutic protein throughout the body, including the central nervous system. AveroBio's first-in-class pipeline includes clinical programs for Gaucher disease and Hunter syndrome, as well as a preclinical program for Pompe disease. AveroBio's proprietary plato® gene therapy platform is scalable for planned global commercialization.